Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ArcticZymes Technologies Director's Dealing 2010

Feb 23, 2010

3538_dirs_2010-02-23_7a2dc111-2df1-4a07-b45a-6fa9047df485.html

Director's Dealing

Open in viewer

Opens in your device viewer

Notification of trade primary insider

Scientific Advisor of Biotec Pharmacon, Dr. Rolf

Seljelid, has today purchased 25,000 shares in the

Company at an average price of NOK 4.00 per share.

Dr. Seljelid holds 75,000 shares after this

transaction.